First Patient Treated in Clinical Study of OsteoActivator-P Membranes for Accelerated Alveolar Ridge Preservation
Osteo-Pharma today announced that the first patient has been treated for the clinical trial ‘OsteoActivator-P for accelerated localized alveolar ridge preservation’. The study is a randomized prospective clinical trial, comparing OsteoActivator-P coated membranes vs Collagen Membrane-P uncoated for accelerated localized alveolar ridge preservation and will investigate the efficacy and safety of OsteoActivator-P. The study is expected to enroll a total of 16 patients at 2 clinical centers in The Netherlands.
Osteo-Pharma and Emultech announce joint venture to develop First-In-Class disease modifying treatment for Osteoarthritis
Emultech and Osteo-Pharma today announced a joint venture to develop what could be the first disease-modifying treatment for osteoarthritis of the knee.
Osteo-Pharma today announced that it has successfully obtained MREC approval for testing their lead product, OsteoActivator-P, in patients. OsteoActivator-P is a novel coated porcine collagen barrier membrane that will be placed on a dental defect to improve early bone formation.
Successful Preclinical Dental defect study Demonstrates Enhanced Bone Regeneration Properties of OsteoActivator coated collagen membranes
Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, today has announced that it has successfully completed a large preclinical study in mini-pigs, which shows its OsteoActivator coated collagen membranes to effectively promote new bone formation.
Osteo-Pharma Receives Notice of Intention to Grant the New Composition of Matter Patent Covering OsteoActivator® Formulations
Osteo-Pharma BV announced today that it received formal notice that the European Patent Office’s Examining Division issued the formal notification of intention to grant the Osteo-Pharma patent application titled “Compositions and products for use...